NanoViricides Reports Initial Efficacy Results on Its Anti-Influenza Drug
Posted on: Monday, 27 February 2006, 09:00 CST
NanoViricides, Inc. (Pink Sheets:NNVC) announced today that it has been informed of the initial test results of a nanoviricide compound used in its anti-influenza drug, FluCide-I(TM).
In preparation for its upcoming trip to Vietnam (the Company had previously announced the signing of a Memorandum of Understanding with the Government of Vietnam for the development of Bird Flu and Rabies drugs), the Company conducted this study to establish certain performance characteristics of its nanoviricide compound.
The test was a blind study on mice with H2N1 (common influenza) performed at a prestigious institute. Although the complete written report on these test results will be received in about three weeks, management is extremely excited with the initial reported results. Management will provide an update on these studies as soon as the full report is received and studied.
The Company's President, Dr. Anil Diwan stated, "These initial results exceeded our expectations and indicate we are on target to meet the priority goal set by management to develop the worlds leading therapeutics for Influenza A and Bird Flu."
http://www.nanoviricides.com
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for anti-viral therapy. A nanoviricide(TM) is a specially designed, flexible, nanomaterial with or without an encapsulated active pharmaceutical ingredient and a targeting ligand to a specific type of virus, like a guided missile.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.
Source: Business Wire
Related Articles
- Testuff Releases a New Version of its Test Management Software, With a Special Twitter Integration Feature
- Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments
- Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments
- Cassatt Survey Finds Massive Data Center Energy Waste in Development and Test Centers, but 59 Percent Would Consider Turning Off Idle Computers
- Response Genetics Study to Focus on Developing Diagnostic Test Kits for Pancreatic Cancer
- Interleukin Genetics Initiates Program To Develop Genetic Test To Guide More Effective Weight Control In Obese Patients
- Silver Dragon Begins Underground Development and Test Mining of the La Chiva Zone At Its Cerro Las Minitas Silver Project in Durango, Mexico
- Catalyst Pharmaceutical Partners, Inc. Names Vice President of Pharmaceutical Development and Project Management
- Favorable Research Outcomes Prompt Expansion of HepaLife's Influenza Vaccine Initiative
- LSI Industries Inc. And 3M Digital Signage Enter Into a 2006 Business Development Initiative
 |
 |
User Comments (0)
RSS Feeds